Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...
After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts. The biotech on Friday said 65% of its staffers are set to leave the company.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei’s Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 ...
BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...
Sensei Biotherapeutics, Inc. announced key updates regarding its lead program, solnerstotug (SNS-101), a treatment targeting the immune checkpoint VISTA in advanced solid tumors. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results